Market Overview

Brean Capital Says Regeneron Pharma Robust Pipeline Drives Upside, Calls Out Dupilumab As Next Catalyst

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Latest Ratings for REGN

DateFirmActionFromTo
Feb 2018Canaccord GenuityDowngradesBuyHold
Feb 2018BMO CapitalMaintainsMarket PerformMarket Perform
Feb 2018Morgan StanleyMaintainsEqual-WeightEqual-Weight

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

Posted-In: Analyst Color Price Target Reiteration Analyst Ratings

 

Related Articles (REGN)